$0.0410
-0.005-10.87%
Last update: Nov 12, 2:22 PM
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals, Inc.
PVCTOTCQB
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals fell 27.5% from $0.06 to $0.05, behind the S&P 500's +11.2%. Its worst day was Nov 25 (−19.7%), and its low came Feb 6 at $0.04.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.00 was reported on $0.00 revenue.
+1.6% · S&P 500 −1.7%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals shares fell 19.7%, while the S&P 500 rose 0.9%.
Story events cover the past 12 months · Times ET
−19.7%, the year's worst day · S&P 500 +0.9%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals closed at its highest level of the year, 13.4% above where the year started.
+4.3% · S&P 500 +0.1%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals shares rose 14.1%, while the S&P 500 rose 0.2%.
+14.1% · S&P 500 +0.2%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals shares fell 14.5%, while the S&P 500 rose 0.5%.
−14.5% · S&P 500 +0.5%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals closed at its lowest level of the year, 39.5% below where the year started.
−8.6% · S&P 500 +1.9%
EPS of $0.00 was reported on $0.00 revenue.
+4.3% · S&P 500 −1.7%
PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals shares rose 14.9%, while the S&P 500 rose 0.0%.
+14.9% · S&P 500 0.0%
EPS of $0.00 was reported on $0.00 revenue.
+1.3% · S&P 500 +0.8%
EPS of $0.00 was reported on $0.00 revenue.
−3.1% · S&P 500 +0.7%
Where it ended: a close of $0.05 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All PVCT analyst actionsNothing in the past 12 months.
All PVCT dividend historyNothing in the past 12 months.
All PVCT newsChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PVCT and SPY from Benzinga historical bars. Not investment advice.
